| Health / Medical Topics |
Alkylating Agent-Related Myelodysplastic Syndrome
A disorder seen following cancer chemotherapy. It is the most common cause of therapy-related myelodysplastic syndromes. It typically manifests several years after initiation of single or multi-agent chemotherapy with alkylators. Mutagenic potential of alkylating agents is believed to be age and cumulative dose-dependent. Deletions in chromosomes 5 and 7 are associated with susceptibility to this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course may progress to bone marrow failure or acute myeloid leukemia that is refractory to treatment. Prognosis is dismal with survivability usually less than one year. (NCI Thesaurus)
YOU MAY ALSO LIKE
Acute myeloid leukemias and myelodysplastic syndromes arising as a result of the mutagenic effect of alkylating agents that are used for the…
A type of drug that is used in the treatment of cancer. It interferes with the cell's DNA and inhibits cancer cell…
A substance that inhibits Alkyl-Guanine Transferase, an enzyme involved with DNA repair.
A drug used to treat multiple myeloma. It is also used to treat ovarian epithelial cancer that cannot be removed by…
A drug used to treat multiple myeloma in patients who cannot take melphalan by mouth. It is also being studied in the…
A drug that is used to treat multiple myeloma and ovarian epithelial cancer and is being studied in the treatment of other…
